Trial Profile

A Phase I pharmacokinetic study of JHL1149 in China

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 29 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Oct 2018 National Medical Products Administration of the PRC (NMPA) has approved Phase I and Phase III Clinical Trial Application for JHL1149.
16 Apr 2018 According to a JHL Biotech media release, the China Food and Drug Administration (CFDA) has accepted for review JHL's Clinical Trial Application for a proposed bevacizumab biosimilar, JHL1149, to treat cancer.
16 Apr 2018 According to a JHL Biotech media release, the data from this and other trials will support the global registration and commercialization of JHL1149.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com